Sientra, Inc. (NASDAQ: SIEN) shares rocket 82% as the medical aesthetics company achieves a significant milestone with their AlloX2 Pro Tissue Expander.

This groundbreaking product has received 510k clearance from the FDA, making it the first and only MRI-compatible tissue expander available on the US market. By utilizing proprietary dual port technology and reducing 95% of the metal typically associated with tissue expander ports, the AlloX2 Pro expands on the success of Sientra’s AlloX2 tissue expander. This innovative design allows the AlloX2 Pro to be labeled as MRI-conditional, enabling breast reconstruction patients to undergo magnetic resonance imaging, an essential screening tool. The AlloX2 Pro also boasts additional features, such as minimal interference with radiation therapy, faster port filling and drainage, and a softer drain for improved patient comfort.
Renowned plastic surgeon Dr. Thomas McClellan, the inventor of AlloX2, expressed pride in partnering with Sientra to bring the AlloX2 Pro to market. He acknowledged Sientra’s commitment to women’s health and technological advancements in breast reconstruction as crucial factors in realizing this critical innovation for post-mastectomy women.
To Discover the Inside Scoop on SIEN, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Dr. Thomas Davenport, a leading plastic surgeon specializing in reconstruction, hailed the AlloX2 Pro as a remarkable advancement in tissue expander technology. The dual ports and MRI compatibility of the AlloX2 Pro offer superior treatment options, improved safety, and expanded usage opportunities for patients who previously faced limitations.
The FDA clearance of the AlloX2 Pro tissue expander marks another significant achievement for Sientra. It underscores the company’s dedication to women’s health, innovation, and leadership in breast reconstruction. Ron Menezes, President and CEO of Sientra, highlighted the company’s track record of introducing innovative solutions for plastic surgeons and their patients, with the AlloX2 Pro being the third product cleared or approved by the FDA within the past year. Sientra aims to provide this groundbreaking technology to its customers and continue its market share growth in reconstruction, which has already reached a record high of 23% by the end of Q1.
What’s retail saying?
As is often the case with significant gains like this, it has garnered considerable attention from the retail crowd, leading many day traders to seek potential entry points actively. However, some traders exhibit caution due to specific emerging negative technical indicators.
Before today’s news, some traders knew $SIEN’s potential and scored an incredible 92% gain. However, it is essential to approach the trading landscape with a discerning eye. While reputable day traders offer valuable insights and guidance, it is crucial to exercise caution due to opportunistic individuals seeking to capitalize on unsuspecting investors for their own financial gain.
https://twitter.com/dbr_land/status/1666916557463642113?s=20
Some traders are eager to exploit the situation by trying to trap bearish investors and create a short squeeze. One trader specifically pointed out that about 1.5 million shorts are stuck in the stock, which represents over 15% of the total available shares for trading, estimated to be around 10 million. This means there’s a chance for a big jump in buying activity, causing the stock price to rise rapidly and forcing those who bet against it to scramble and cover their positions. It’s an interesting situation that could lead to exciting market action.
Overview of Sientra
Based in Irvine, California, Sientra is a medical aesthetics company focusing exclusively on plastic surgery. Their goal is to bring groundbreaking advancements to plastic surgeons, transforming how they approach their work and care for their patients. Sientra has built various products that stand out due to their unique technology and have undergone rigorous testing and clinical trials. Some of their notable products include Sientra round and shaped breast implants, the first fifth-generation implants approved by the FDA for sale in the United States. They have also developed the innovative AlloX2 breast tissue expander, featuring dual-port and integral drain technology. Additionally, Sientra offers the Viality system for enhanced fat transfer, the SimpliDerm Human Acellular Dermal Matrix, and BIOCORNEUM, a scar gel highly regarded and recommended by plastic surgeons.
Sientra’s recent update is an extraordinary accomplishment, as it marks the company’s third successful product clearance within a mere 12-month period. This consistent stream of successful product clearances highlights the company’s commitment to innovation and underscores its position as a leader in the industry. Furthermore, Sientra’s market share in the breast reconstruction segment has already surged to an impressive 23% by the end of the first quarter. This substantial market presence signifies the growing recognition and acceptance of Sientra’s offerings among healthcare professionals and patients. It serves as a testament to the company’s ability to deliver effective and sought-after solutions in the field of breast reconstruction.
We will update you on SIEN when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by WikiImages from Pixabay